DIA DIRECT: Risk-Based Thinking in Clinical Trials

Risk-based thinking is the key to focusing sponsor resources on the sites that need the most attention. Determining which sites those are and how to best address the risks they present requires advanced digital solutions, including artificial intelligence (AI) and machine learning (ML).

Presenters

Matt Lowe

Chief Product Officer, MasterControl, United States

Medical device expert Matt Lowe joined MasterControl in 2006. Since then, he has served in a variety of executive leadership positions in global sales, marketing, and product development. In his current role, Matt is responsible for all aspects of design and development of MasterControl’s software solution. His career includes product development and product management at Ortho Development Corp. and at Bard Access Systems, now BD. He successfully launched more than a dozen medical devices and has five patents issued and one pending. Matt has a bachelor's degree in mechanical engineering from the University of Utah and an MBA from Indiana University.

Ansalan Stewart, PhD

Health Scientist Policy Analyst, OMP, CDER, FDA, United States

MaryAnne Rizk, PhD

Chief Executive Officer, Rizk Management Advisors, United States

Dr. MaryAnne Rizk builds large-scale partner ecosystems at the intersection of science & technology. A PharmaVoice™ 100 Award Recipient, she champions change and collaboration, accelerating scientific breakthroughs from pipeline to patient. With 25 years in digital transformations at CVS Health, Merck, Oracle, Medidata, IQVIA, and Medable, she has expertise in expanding commercial growth & SaaS adoption. She developed top strategic programs influencing global partner ecosystems and education.